Brought to you by 
Series D raises $25mm for Tethys; adds $23mm
22 Jul 2010
Executive Summary
Tethys Bioscience, developer of the PreDx diabetes risk score test, raised $25mm in its Series D financing led by first-time backer Aeris Capital AG, which adds a board member. Other new investor Wasatch Advisors was joined by returning shareholders Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers, and Intel Capital. Money from the round will be used to expand commercialization activities for PreDx, which can determine patients who are at risk for developing Type II diabetes within five years.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D raises $25mm for Tethys; adds $23mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice